Cox J D, Pajak T F, Marcial V A, Hanks G E, Mohiuddin M, Fu K K, Byhardt R W, Rubin P
U.T.M.D. Anderson Cancer Center, Office of Vice President for Patient Care, Houston, TX 77030.
Int J Radiat Oncol Biol Phys. 1990 Mar;18(3):515-21. doi: 10.1016/0360-3016(90)90054-n.
A prospective, randomized Phase Ilate/II trial of hyperfractionated radiation therapy was conducted: 1.2 Gy minimum tumor dose was administered twice daily with a minimum interval of 4 hr, 5 days per week. Patients with Stage III and IV carcinomas of the oral cavity, oropharynx, nasopharynx, hypopharynx, and supraglottic larynx were stratified by site, presence or absence of nodal metastases, and performance status. They were assigned to four total doses between 67.2 Gy and 81.6 Gy to all known tumors. The highest dose arm was opened after preliminary assessment indicated acceptable late morbidity rates with the three lower doses. Of 479 patients entered, 260 patients were randomized to the three lower total doses and 237 were analyzed for this preliminary report: 63 were assigned to receive 67.2 Gy, 58 to 72.0 Gy, and 116 to 76.8 Gy. Estimates of grade 4 necrosis at 2 years were 10.0%, 5.1%, and 13.9%, respectively, for patients who received total doses of 67.2 Gy, 72.0 Gy, and 76.8 Gy. There was a suggestion of a trend toward increased local control at 24 months (Kaplan-Meier estimates of 25% for 67.2 Gy, 37% for 72.0 Gy, and 42% for 76.8 Gy) (p = .08). No difference was observed in survival. Assessment of the results using Cox regression models to correct for slight inequalities of pretreatment prognostic variables supported a total dose-tumor control relationship (p = .054). Results for the lowest dose arm were comparable to previous RTOG studies of common fractionation with similar total doses. The higher local control rates with 72.0 and 76.8 Gy using hyperfractionated radiation therapy suggest an improvement in outcome with radiation therapy for advanced carcinomas of the upper aerodigestive tracts. These preliminary findings have led to a Phase III comparison of hyperfractionated radiation therapy with 1.2 Gy b.i.d. with standard fractionation.
开展了一项前瞻性随机II期晚期/II期超分割放射治疗试验:最小肿瘤剂量为1.2 Gy,每天给药两次,最小间隔4小时,每周5天。口腔、口咽、鼻咽、下咽和声门上喉III期和IV期癌患者按部位、有无淋巴结转移及体能状态进行分层。所有已知肿瘤被分配至4个总剂量组,总剂量在67.2 Gy至81.6 Gy之间。在初步评估显示三个较低剂量组的晚期发病率可接受后,开启了最高剂量组。在入组的479例患者中,260例患者被随机分配至三个较低总剂量组,本初步报告分析了237例:63例被分配接受67.2 Gy,58例接受72.0 Gy,116例接受76.8 Gy。接受总剂量67.2 Gy、72.0 Gy和76.8 Gy的患者在2年时4级坏死的估计发生率分别为10.0%、5.1%和13.9%。在24个月时,有局部控制增加趋势的迹象(67.2 Gy的Kaplan-Meier估计值为25%,72.0 Gy为37%,76.8 Gy为42%)(p = 0.08)。未观察到生存差异。使用Cox回归模型评估结果以校正预处理预后变量的轻微不平等,支持总剂量与肿瘤控制的关系(p = 0.054)。最低剂量组的结果与既往RTOG总剂量相似的常规分割研究相当。超分割放射治疗72.0 Gy和76.8 Gy时较高的局部控制率表明,上呼吸消化道晚期癌的放射治疗结果有所改善。这些初步发现促成了一项III期比较,即1.2 Gy bid超分割放射治疗与标准分割治疗的比较。